Skip to content
OpenCapital
Get started

Biogen BIIB Interferon — Total Revenue

Other product segments

TYSABRI
$441.5M+15.7%
SPINRAZA
$374M-11.8%
VUMERITY
$179M+29.0%
AVONEX
$163.2M-2.2%
SKYCLARYS
$150.7M+21.6%
BENEPALI
$122.1M+9.7%
TECFIDERA
$109.5M-46.9%
PLEGRIDY
$64.3M+8.1%
ZURZUVAE
$55.4M+100%
IMRALDI
$49.6M+4.6%
QALSODY
$32.5M+110%
FLIXABI
$10.5M-19.8%
BYOOVIZ
$0-100%
FAMPYRA
$0-100%
FUMADERM And ADUHELM
$0-100%
TOFIDENCE
$0-100%

Similar metrics at other companies

Insulet logo
PODDInternational — Total Revenue
$242.9M+59.5%
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$700K+16.7%
Gilead Sciences logo
GILDTotal HIV — Total revenues
$5.03B+9.7%
Gilead Sciences logo
GILDOdefsey — Total revenues
$221M-21.4%
Gilead Sciences logo
GILDTotal Liver Disease — Total revenues
$767M+1.2%
Gilead Sciences logo
GILDSofosbuvir/Velpatasvir — Total revenues
$283M-18.2%

Other financials

Income statement

See full
Revenue$2.5B+1.9%
Gross profit$1.8B+0.8%
Operating income$610.7M—
Net income$319.5M+32.8%
EPS (diluted)$2.15+31.1%

Balance sheet

See full
Cash & equivalents$3.4B+30.2%
Total debt$6.6B+34.7%
Total equity$18.7B+9.9%
Total assets$29.5B+5.2%

Cash flow

See full
Operating cash flow$645.5M+149%
CapEx$51.2M+38.0%
Free cash flow$594.3M+167%

Valuation

See full
Market cap$31.89B+72.3%
Enterprise value$35.07B+57.0%
P/E22.5×+10.4×
P/S3.2×+1.4×

Profitability

See full
Gross margin75.5%-0.1pp
Operating margin22.9%—
Net margin14.3%-0.8pp
FCF margin24.4%-0.4pp

Returns & leverage

See full
Return on equity8%-1.2pp
Debt / equity0.4×+0.1×
Current ratio3.1×+1.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's interferon — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's interferon — total revenue?
Biogen (BIIB) reported interferon — total revenue of $227.5M in Q1 2026.
How has Biogen's interferon — total revenue changed year-over-year?
Biogen's interferon — total revenue increased by 0.5% year-over-year, from $226.3M to $227.5M.
What is the long-term trend for Biogen's interferon — total revenue?
Over 4 years (2021 to 2025), Biogen's interferon — total revenue has grown at a -11.9% compound annual growth rate (CAGR), from $1.57B to $945.6M.
What does interferon — total revenue mean?
This metric represents the total gross revenue generated from the sale of interferon-based therapeutic products within the company's multiple sclerosis portfolio. It reflects the market performance and commercial adoption of these specific legacy treatments as they face competition from newer oral and infusion-based therapies. This revenue stream is a critical indicator of the company's ability to maintain market share in the mature multiple sclerosis segment.